# US 2010/0143368 A1 · Human Antibodies That Bind Cd22 And Uses Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0143368 A1
- Document ID: US20100143368A1
- Status: Published application
- Kind: A1
- Application number: 12/517,183
- Filed: 2007-11-30
- Published: 2010-06-10
- Earliest claimed: 2006-12-01
- Assignees: Medarex, Inc.
- Inventors: David John King; Alison Witte; Heidi N. LeBlanc; Richard Theolis; Asna Masood; Mark Yamanaka; Kyra D. Emory; Sarah R. Reed; Tim Sproul; Chetana Rao-Naik; David Passmore
- Web page: https://patentgrep.com/patent/US20100143368A1

## CPC

- C07K 16/2803: {against the immunoglobulin superfamily}
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/6829: {Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 51/1027: {against receptors, cell-surface antigens or cell-surface determinants}
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 16/3061: {Blood cells}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/41: Glycosylation, sialylation, or fucosylation
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/70: characterized by effect upon binding to a cell or to an antigen
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/734: Complement-dependent cytotoxicity [CDC]
- C07K 2317/77: Internalization into the cell
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure provides isolated monoclonal antibodies that specifically bind to CD22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD22, as well as methods for treating various cancers and inflammatory and autoimmune disorders using an anti-CD22 antibody of this disclosure.

## Claims

### Claim 1

An isolated human monoclonal antibody, or an antigen-binding portion thereof, wherein the antibody binds human CD22 and exhibits at least one of the following properties:
(a) internalizes into CD22+ cells;
(b) exhibits antibody dependent cellular cytotoxicity (ADCC) against CD22+ cells;
(c) enhances cell death of Ramos cells induced by B cell receptor (BCR) stimulation;
(d) inhibits growth of CD22-expressing cells in vivo when conjugated to a cytotoxin; and
(e) binds to human CD22 with a KD of 5×10−8 M or less.

### Claim at position 2

-9. (canceled)

### Claim 10 (depends on 1)

The isolated human monoclonal antibody, or antigen binding portion thereof, of claim 1 wherein the antibody cross-competes for binding to an eptiope on CD22 recognized by a reference antibody, wherein the reference antibody comprises:
(a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:31 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:35; or
(b) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:32 or SEQ ID NO:61 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:36; or
(c) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:33 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:37 or 38; or
(d) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:34 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:39 or 40: or
(e) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:81 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:84 or 85: or
(f) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:82 or 83 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:86.

### Claim at position 4

-14. (canceled)

### Claim 15 (depends on 1)

The isolated human monoclonal antibody, or an antigen-binding portion thereof, of claim 1 comprising a heavy chain variable region that is the product of or derived from a human VH gene selected from the group consisting of: a 7-4.1 gene, a 4-34 gene, a 5-51 gene, and a 1-69 gene.

### Claim 16 (depends on 1)

The isolated monoclonal antibody, or an antigen-binding portion thereof, of claim 1 comprising a light chain variable region that is the product of or derived from a human VL gene selected from the group consisting of: a 2b2 gene, an L6 gene, an A27 gene, an A10 gene, and an L18 gene.

### Claim 17

(canceled)

### Claim 18 (depends on 1)

The isolated human monoclonal antibody, or an antigen-binding portion thereof, of claim 1, which comprises:
(a) a heavy chain variable region CDR1 comprising SEQ ID NO:1;
(b) a heavy chain variable region CDR2 comprising SEQ ID NO:5;
(c) a heavy chain variable region CDR3 comprising SEQ ID NO:9;
(d) a light chain variable region CDR1 comprising SEQ ID NO:13;
(e) a light chain variable region CDR2 comprising SEQ ID NO:19; and
(f) a light chain variable region CDR3 comprising SEQ ID NO:25; or
(g) a heavy chain variable region CDR1 comprising SEQ ID NO:2;
(h) a heavy chain variable region CDR2 comprising SEQ ID NO:6 or SEQ ID NO:60;
(i) a heavy chain variable region CDR3 comprising SEQ ID NO:10;
(j) a light chain variable region CDR1 comprising SEQ ID NO:14;
(k) a light chain variable region CDR2 comprising SEQ ID NO:20; and
(l) a light chain variable region CDR3 comprising SEQ ID NO:26; or
(m) a heavy chain variable region CDR1 comprising SEQ ID NO:3;
(n) a heavy chain variable region CDR2 comprising SEQ ID NO:7;
(o) a heavy chain variable region CDR3 comprising SEQ ID NO:11;
(p) a light chain variable region CDR1 comprising SEQ ID NO:15 or 16;
(q) a light chain variable region CDR2 comprising SEQ ID NO:21 or 22; and
(r) a light chain variable region CDR3 comprising SEQ ID NO:27 or 28; or
(s) a heavy chain variable region CDR1 comprising SEQ ID NO:4,
(t) a heavy chain variable region CDR2 comprising SEQ ID NO:8;
(u) a heavy chain variable region CDR3 comprising SEQ ID NO:12;
(v) a light chain variable region CDR1 comprising SEQ ID NO:17 or 18;
(w) a light chain variable region CDR2 comprising SEQ ID NO:23 or 24; and
(x) a light chain variable region CDR3 comprising SEQ ID NO:29 or 30; or
(y) a heavy chain variable region CDR1 comprising SEQ ID NO:63;
(z) a heavy chain variable region CDR2 comprising SEQ ID NO:66;
(aa) a heavy chain variable region CDR3 comprising SEQ ID NO:69;
(bb) a light chain variable region CDR1 comprising SEQ ID NO:72 or 73;
(cc) a light chain variable region CDR2 comprising SEQ ID NO:75 or 76; and
(dd) a light chain variable region CDR3 comprising SEQ ID NO:78 or 79; or
(ee) a heavy chain variable region CDR1 comprising SEQ ID NO:64 or 65;
(ff) a heavy chain variable region CDR2 comprising SEQ ID NO:67 or 68;
(gg) a heavy chain variable region CDR3 comprising SEQ ID NO:70 or 71;
(hh) a light chain variable region CDR1 comprising SEQ ID NO:74;
(ii) a light chain variable region CDR2 comprising SEQ ID NO:77; and
(jj) a light chain variable region CDR3 comprising SEQ ID NO:80.

### Claim at position 9

-27. (canceled)

### Claim 28 (depends on 1)

The antibody, or antigen-binding portion thereof, of claim 1, wherein the isolated human monoclonal antibody, or antigen binding portion thereof, is linked to a partner molecule, wherein the partner molecule is a therapeutic agent.

### Claim 29

(canceled)

### Claim 30 (depends on 28)

The isolated human monoclonal antibody, or antigen binding portion thereof, of claim 28, wherein the therapeutic agent is a cytotoxin.

### Claim 31

(canceled)

### Claim 32 (depends on 28)

The isolated human monoclonal antibody, or antigen binding portion thereof of claim 28, wherein the therapeutic agent is a radioactive isotope.

### Claim 33

-37. (canceled)

### Claim 38 (depends on 1)

A method of inhibiting growth of a CD22-expressing tumor cell, the method comprising contacting the CD22-expressing tumor cell with the isolated human monoclonal antibody, or antigen-binding portion thereof, of claim 1 such that growth of the CD22-expressing tumor cell is inhibited.

### Claim 39 (depends on 38)

The method of claim 38, wherein the tumor cell is a B cell lymphoma.

### Claim 40 (depends on 39)

The method of claim 39, wherein the B cell lymphoma is a non-Hodgkin's lymphoma.

### Claim 41 (depends on 38)

The method of claim 38, wherein the antibody, or antigen-binding portion thereof, is conjugated to a therapeutic agent.

### Claim 42 (depends on 41)

The method of claim 41, wherein the therapeutic agent is a cytotoxin.

### Claim 43 (depends on 1)

A method of treating an inflammatory or autoimmune disorder in a subject, the method comprising administering to the subject the isolated human monoclonal antibody, or antigen-binding portion thereof, of claim 1 such that the inflammatory or autoimmune disorder in the subject is treated.

### Claim 44 (depends on 43)

The method of claim 43, wherein the autoimmune disorder is systemic lupus erythematosus.

### Claim 45 (depends on 43)

The method of claim 43, wherein the autoimmune disorder is rheumatoid arthritis.

### Claim at position 24

-54. (canceled)
